Real-World Healthcare Resource Utilization and Costs Associated with Elranatamab Initiation in Multiple Myeloma: the ALTITUDE-1 Study
Author(s)
Rahul Banerjee, MD, FACP1, Meera Mohan, MD, MS2, Bhavesh H. Shah, RPh, BCOP3, Patricia Prince, MPH4, Nileesa Gautam, MS4, Brian Conroy, PhD4, Elisha Beebe, BS4, David Hughes, PharmD5, Guido Nador, MD6, Patrick Hlavacek, MPH7, Rickard Sandin, PhD8, Benjamin Li, MD7, Aster Meche, MPH7, Chai Hyun Kim, MPH7, Isabel Perez Cruz, PhD7, Mohsena Sumaya, PharmD, MBA7, Marco DiBonaventura, PhD7.
1Fred Hutchinson Cancer Center, Seattle, WA, USA, 2Medical College of Wisconsin, Milwaukee, WI, USA, 3Boston Medical Center, Boston, MA, USA, 4Aetion, New York, NY, USA, 5Pfizer Inc, Cambridge, MA, USA, 6Pfizer Ltd, Surrey, United Kingdom, 7Pfizer Inc, New York, NY, USA, 8Pfizer AB, Stockholm, Sweden.
1Fred Hutchinson Cancer Center, Seattle, WA, USA, 2Medical College of Wisconsin, Milwaukee, WI, USA, 3Boston Medical Center, Boston, MA, USA, 4Aetion, New York, NY, USA, 5Pfizer Inc, Cambridge, MA, USA, 6Pfizer Ltd, Surrey, United Kingdom, 7Pfizer Inc, New York, NY, USA, 8Pfizer AB, Stockholm, Sweden.
Presentation Documents
OBJECTIVES: Elranatamab-bcmm (ELRA) is a bispecific antibody approved in the US for the treatment of relapsed/refractory multiple myeloma (RRMM). While ELRA is associated with improved clinical outcomes compared with standard regimens in real-world (RW) practice (Costa et al, ASH 2024), ELRA’s impact on healthcare resource utilization (HCRU) and costs are unclear.
METHODS: ALTITUDE-1 (EUPAS1000000229) is an ongoing, non-interventional database study designed to assess RW treatment patterns, HCRU, and costs (among other outcomes) of patients with RRMM treated with ELRA. The data source was the Komodo US claims dataset with the initiation of ELRA set as the index date. This interim analysis descriptively reported the changes in HCRU and costs from pre-index (180 days prior) to post-index (while treated with ELRA) on a per-patient-per-month (PPPM) basis.
RESULTS: As of August 2024, 32 patients treated with ELRA were included (median age=75.5 years, 59.4% female, 59.4% White, 21.9% African American). Half (50.0%) of patients were penta-drug exposed and 28.1% had received prior commercial BCMA-directed therapy. The median number of all-cause inpatient visits increased from pre-index (0.42 PPPM; IQR 0.17-1.71) to post-index (1.55 PPPM; IQR 0-2.76), while all-cause outpatient visits remained stable (medians=2.42 versus 2.62 PPPM). Total median all-cause medical and pharmacy costs also remained stable from pre-index ($11,390 PPPM; IQR $4682-$30,365) to post-index ($10,694; IQR $6203-$29,888). However, the changes within cost categories varied. Median all-cause inpatient costs numerically decreased from pre-index ($1379 PPPM; IQR $28-$3808) to post-index ($957 PPPM; IQR $0-$5730), as did median all-cause pharmacy costs ($491 PPM; IQR $84-$11,592 versus $192 PPM; IQR $33-$549), while all-cause outpatient costs increased slightly from pre-index ($4945 PPPM; IQR $1659-$12,993) to post-index ($5738 PPPM; IQR $1614-$22,219).
CONCLUSIONS: While the total costs of care remain roughly stable after the initiation of ELRA, the categories of costs evolve. Interestingly, pharmacy costs decreased after ELRA initiation.
METHODS: ALTITUDE-1 (EUPAS1000000229) is an ongoing, non-interventional database study designed to assess RW treatment patterns, HCRU, and costs (among other outcomes) of patients with RRMM treated with ELRA. The data source was the Komodo US claims dataset with the initiation of ELRA set as the index date. This interim analysis descriptively reported the changes in HCRU and costs from pre-index (180 days prior) to post-index (while treated with ELRA) on a per-patient-per-month (PPPM) basis.
RESULTS: As of August 2024, 32 patients treated with ELRA were included (median age=75.5 years, 59.4% female, 59.4% White, 21.9% African American). Half (50.0%) of patients were penta-drug exposed and 28.1% had received prior commercial BCMA-directed therapy. The median number of all-cause inpatient visits increased from pre-index (0.42 PPPM; IQR 0.17-1.71) to post-index (1.55 PPPM; IQR 0-2.76), while all-cause outpatient visits remained stable (medians=2.42 versus 2.62 PPPM). Total median all-cause medical and pharmacy costs also remained stable from pre-index ($11,390 PPPM; IQR $4682-$30,365) to post-index ($10,694; IQR $6203-$29,888). However, the changes within cost categories varied. Median all-cause inpatient costs numerically decreased from pre-index ($1379 PPPM; IQR $28-$3808) to post-index ($957 PPPM; IQR $0-$5730), as did median all-cause pharmacy costs ($491 PPM; IQR $84-$11,592 versus $192 PPM; IQR $33-$549), while all-cause outpatient costs increased slightly from pre-index ($4945 PPPM; IQR $1659-$12,993) to post-index ($5738 PPPM; IQR $1614-$22,219).
CONCLUSIONS: While the total costs of care remain roughly stable after the initiation of ELRA, the categories of costs evolve. Interestingly, pharmacy costs decreased after ELRA initiation.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE85
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology